Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Teva Pharmaceutical Industries Limited < Previous 1 2 3 4 5 Next > Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting November 07, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reports Third Quarter 2022 Financial Results November 03, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC October 25, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease October 18, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reaches Agreement With Arkansas to Settle the State’s Price Fixing Claims October 07, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022 October 06, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes October 06, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims September 30, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea September 26, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression September 08, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management September 07, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022 August 29, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in developed countries August 29, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reports Second Quarter 2022 Financial Results July 26, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims July 12, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Appointment of New Global R&D and Chief Medical Officer July 01, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022 June 29, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute June 09, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Presented at 2022 American Headache Society Annual Meeting June 09, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting June 09, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services June 08, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims May 25, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting May 23, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼ May 17, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting May 17, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges May 17, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting May 12, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure May 10, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reports First Quarter 2022 Financial Results May 03, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute May 02, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.